Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on November 15, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 91,500 shares of its common stock to two new non-executive employees to induce them to accept employment with Vaxart.
2024年11月19日，加州南舊金山（GLOBE NEWSWIRE）— vaxart公司（Nasdaq: VXRT）（"公司"或"vaxart"）今日宣佈，董事會薪酬委員會於2024年11月15日授予了91100股公司普通股的誘因股權獎勵，以激勵兩名新的非高管僱員接受vaxart的僱傭。
The awards consisted of stock options to purchase an aggregate of 61,000 shares of Vaxart's common stock, which vest as to 1/4th of the total shares on the one-year anniversary of the grant date, and as to 1/48th of the total shares on each month thereafter, and have a per share exercise price equal to the closing price of Vaxart's common stock on the grant date; and restricted stock unit awards covering an aggregate of 30,500 shares of Vaxart's common stock, which vest as to 25% of the shares underlying the awards on the first, second, third and fourth anniversary of the grant date.
這些獎勵包括購買vaxart公司61000股普通股的期權，這些期權的總股數在授予日的一年週年時解禁1/4，其後每個月解禁總股數的1/48，並且每股行使價格等於授予日vaxart普通股的收盤價；以及涵蓋vaxart公司30500股普通股的限制性股票單位獎勵，這些獎勵將在授予日後的第一、第二、第三和第四週年時解鎖這些獎勵股票的25%。
The awards were granted under the Vaxart, Inc. 2024 Inducement Award Plan as an employment "inducement award" pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Vaxart (or following a bona fide period of non-employment) as an inducement material to entering into employment with Vaxart.
這些獎勵是根據納斯達克納斯達克公司2024年誘因獎勵計劃授予的，作爲僱傭"誘因獎勵"，依據納斯達克上市規則5635(c)(4)。誘因計劃專門用於授予股權獎勵給以前不是vaxart的僱員（或在真實的非僱傭期後）作爲誘因，進入vaxart僱傭。
About Vaxart
Vaxart是一家臨床階段的生物技術公司，開發一系列基於其專有遞送平台的口服重組疫苗。Vaxart的疫苗是設計爲使用藥丸進行管理的，這些藥丸可以在沒有冷藏的情況下存儲和運輸，並消除了針刺傷的風險。Vaxart相信，其專有的藥丸疫苗遞送平台適合遞送重組疫苗，使公司能夠開發當前已上市的疫苗的口服版，併爲新的適應症設計重組疫苗。Vaxart的研發計劃目前包括用於保護人類免受冠狀病毒、諾如病毒和流感的藥丸疫苗，以及HPV的治療性疫苗，這是Vaxart的首個免疫腫瘤學適應症。
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and to eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Vaxart是一家臨床階段的生物技術公司，正在開發一系列基於其專有遞送平台的口服重組疫苗。Vaxart的疫苗設計爲使用可以在無需冷藏的情況下存儲和運輸的藥丸進行注射，並消除了針刺傷的風險。Vaxart相信其專有的藥丸疫苗遞送平台適用於提供重組疫苗，使該公司能夠開發目前已上市疫苗的口服版本，並設計適用於新適應症的重組疫苗。Vaxart目前的開發計劃包括用於預防冠狀病毒、諾如病毒和流感的藥丸疫苗，以及用於人乳頭瘤病毒(HPV)的治療性疫苗，這是Vaxart的首個免疫腫瘤學適應症。Vaxart已提交廣泛的國內和國際專利申請，涵蓋其口服疫苗使用腺病毒和TLR3激動劑的專有技術和創作。
Contact
聯繫方式
Vaxart Media and Investor Relations:
Matt Steinberg
FINN Partners
IR@vaxart.com
(646) 871-8481
vaxart媒體和投資者關係:
Matt Steinberg
FINN Partners
IR@vaxart.com
（646）871-8481
This press release was published by a CLEAR Verified individual.
此新聞發佈是由經過驗證的個人發佈的。
譯文內容由第三人軟體翻譯。
